Literature DB >> 25653410

Improving the sensitivity of the Xpert MTB/RIF assay on sputum pellets by decreasing the amount of added sample reagent: a laboratory and clinical evaluation.

Nila J Dharan1, Danielle Amisano2, Gerald Mboowa3, Willy Ssengooba3, Robert Blakemore2, Rachel W Kubiak4, Derek T Armstrong5, Martin Jones6, Yukari C Manabe7, Moses L Joloba3, Jerrold J Ellner8, Susan E Dorman7, David Alland2.   

Abstract

The Xpert MTB/RIF (Xpert) assay permits rapid near-patient detection of Mycobacterium tuberculosis in sputum; however, the test sensitivity remains suboptimal in paucibacillary specimens that are negative for acid-fast bacilli using smear microscopy. Xpert testing includes dilution with sample reagent, and when processed sputum pellets are tested, the recommended sample reagent/pellet ratio is 3:1. We evaluated whether a decreased sample reagent/pellet ratio of 2:1 increased Xpert sensitivity compared to the recommended 3:1. The limit of detection was determined by inoculating serial dilutions of M. tuberculosis into sputum samples, preparing sputum pellets, and testing each pellet by Xpert at both sample reagent ratios. Processed sputum pellets obtained from M. tuberculosis culture-positive clinical specimens were also tested by Xpert at both ratios. Among spiked sputum pellets, the limit of detection was 1,478 CFU/ml (95% confidence interval [CI], 1,211 to 1,943) at a 3:1 ratio and decreased to 832 CFU/ml (95% CI, 671 to 1,134) at 2:1. The proportion of specimens in which M. tuberculosis was detected was greater at 2:1 than at 3:1 for almost all numbers of CFU/ml; this difference was most prominent at lower numbers of CFU/ml. Among 134 concentrated sputum pellets from the clinical study, the sensitivity of Xpert at 2:1 was greater than at 3:1 overall (80% versus 72%; P=0.03) and for smear-negative specimens (67% versus 58%; P=0.12). For Xpert testing of sputum pellets, using a lower sample reagent/pellet ratio increased M. tuberculosis detection, especially for paucibacillary specimens. Our study supports use of a 2:1 sample reagent/pellet dilution for Xpert testing of sputum pellets.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25653410      PMCID: PMC4365264          DOI: 10.1128/JCM.03619-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis.

Authors:  Moises Palaci; Reynaldo Dietze; David Jamil Hadad; Fabiola Karla Corrêa Ribeiro; Renata Lyrio Peres; Solange Alves Vinhas; Ethel Leonor Noia Maciel; Valdério do Valle Dettoni; Libby Horter; W Henry Boom; John L Johnson; Kathleen D Eisenach
Journal:  J Clin Microbiol       Date:  2007-10-10       Impact factor: 5.948

2.  Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults.

Authors:  Lydia Nakiyingi; Vineshree Mischka Moodley; Yukari C Manabe; Mark P Nicol; Molly Holshouser; Derek T Armstrong; Widaad Zemanay; Welile Sikhondze; Olive Mbabazi; Bareng A S Nonyane; Maunank Shah; Moses L Joloba; David Alland; Jerrold J Ellner; Susan E Dorman
Journal:  J Acquir Immune Defic Syndr       Date:  2014-07-01       Impact factor: 3.731

Review 3.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

4.  Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression.

Authors:  Colleen F Hanrahan; Grant Theron; Jean Bassett; Keertan Dheda; Lesley Scott; Wendy Stevens; Ian Sanne; Annelies Van Rie
Journal:  Am J Respir Crit Care Med       Date:  2014-06-01       Impact factor: 21.405

5.  Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata.

Authors:  G Chamie; A Luetkemeyer; M Walusimbi-Nanteza; A Okwera; C C Whalen; R D Mugerwa; D V Havlir; E D Charlebois
Journal:  Int J Tuberc Lung Dis       Date:  2010-10       Impact factor: 2.373

6.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

7.  Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology.

Authors:  Danica Helb; Martin Jones; Elizabeth Story; Catharina Boehme; Ellen Wallace; Ken Ho; JoAnn Kop; Michelle R Owens; Richard Rodgers; Padmapriya Banada; Hassan Safi; Robert Blakemore; N T Ngoc Lan; Edward C Jones-López; Michael Levi; Michele Burday; Irene Ayakaka; Roy D Mugerwa; Bill McMillan; Emily Winn-Deen; Lee Christel; Peter Dailey; Mark D Perkins; David H Persing; David Alland
Journal:  J Clin Microbiol       Date:  2009-10-28       Impact factor: 5.948

8.  Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.

Authors:  Amina Jindani; Caroline J Doré; Denis A Mitchison
Journal:  Am J Respir Crit Care Med       Date:  2003-01-06       Impact factor: 21.405

9.  Exploring alternative biomaterials for diagnosis of pulmonary tuberculosis in HIV-negative patients by use of the GeneXpert MTB/RIF assay.

Authors:  Shubhada Shenai; Danielle Amisano; Katharina Ronacher; Magdalena Kriel; Padmapriya P Banada; Taeksun Song; Myungsun Lee; Joon Sung Joh; Jill Winter; Rich Thayer; Laura E Via; Soyeon Kim; Clifton E Barry; Gerhard Walzl; David Alland
Journal:  J Clin Microbiol       Date:  2013-10-09       Impact factor: 5.948

10.  Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments.

Authors:  Grant Theron; Jonny Peter; Greg Calligaro; Richard Meldau; Colleen Hanrahan; Hoosain Khalfey; Brian Matinyenya; Tapuwa Muchinga; Liezel Smith; Shaheen Pandie; Laura Lenders; Vinod Patel; Bongani M Mayosi; Keertan Dheda
Journal:  Sci Rep       Date:  2014-07-11       Impact factor: 4.379

View more
  2 in total

1.  Improved performance of Xpert MTB/RIF assay on sputum sediment samples obtained from presumptive pulmonary tuberculosis cases at Kibong'oto infectious diseases hospital in Tanzania.

Authors:  Peter M Mbelele; Said Aboud; Stellah G Mpagama; Mecky I Matee
Journal:  BMC Infect Dis       Date:  2017-12-29       Impact factor: 3.090

2.  Comparative Study of a Real-Time PCR Assay Targeting senX3-regX3 versus Other Molecular Strategies Commonly Used in the Diagnosis of Tuberculosis.

Authors:  Rocio Sanjuan-Jimenez; Inmaculada Toro-Peinado; Pilar Bermudez; Juan D Colmenero; Pilar Morata
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.